28.10.2020
of hydroxychloroquine, especially if combined with azithromycin, for COVID-19. Such treatment may be associated
28.10.2020
There exist some theoretical premises for the use of colchicine in patients with COVID
28.10.2020
At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical
28.10.2020
with mild to moderate COVID-19 is limited to open-label randomized clinical trials. The use of the drug
28.10.2020
27.10.2020
aminodihydrophthalazindione in «cytokine storm», including in patients with COVID-19. Protocols of planned or ongoing clinical
27.10.2020
distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic
27.10.2020
of acute respiratory distress-syndrome in patients with COVID-19, and such treatment is not supported
27.10.2020
No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some
27.10.2020
of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful
